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Abstract: Orthostasis due to autonomic neuropathy can cause severe debilitation and prove 
refractory to treatment. This report describes a case of severe sympathetic and parasympathetic 
autonomic dysfunction as a consequence of acetylcholine receptor antibodies and Sjogren’s 
syndrome. Symptomatic management, plasma ﬂ  uid expanders, and IVIG therapy failed to 
offer a salutary response to the condition. Etanercept therapy provided improvement of the 
orthostasis and autonomic function measured as high and low frequency respiratory effects on 
heart rate variability as well as enhancement of skin blood ﬂ  ow using Laser Doppler. It would 
be of considerable interest to determine the effectiveness of etanercept in other autoimmune 
neuropathies.
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Case presentation
A 41-year-old gentleman with seronegative polyarthritis and Sicca syndrome developed 
intermittent dizziness preceding loss of consciousness within minutes after standing 
up. His eyes and mouth were chronically dry. He became short of breath with mild 
exertion and was unable to sweat. He had chronic constipation, nausea, heartburn, a 
poor appetite, and a 27-pound weight loss in four months. He also had constant foot 
pain, numbness, and swelling as if he were walking barefoot on gravel. He routinely 
lost sleep from persistent nocturia and noted a decrease in penile sensation with an 
inability to ejaculate.
He had chronic nephrolithiasis requiring lithotripsy, stent placement and removal. 
Echocardiography was normal. Cardiac stress testing revealed no ischemia. Chro-
notropic incompetence was present. Bone density scanning had a T-score of −2.3. 
Computed tomography (CT) of the chest/abdomen showed a multifocal increase in 
lymph nodes at the celiac/superior mesenteric arteries and periaortic regions. His 
medications included leﬂ  unomide 20 mg/day, vitamin D 50,000 U/week, calcium 
supplementation 1200 mg/day, and daily folic acid. He was allergic to erythromycin 
with adverse reactions to sulfasalazine and methotrexate.
On physical examination, he was 71½ inches tall and weighed 164 pounds. Supine 
blood pressure was 128/78 mmHg (pulse – 65 beats per minute [bpm]) with a sitting 
blood pressure 118/78 mmHg (pulse – 63 bpm) and standing blood pressure 100/61 
mmHg (pulse – 64 bpm). He was not anemic, cyanosed, jaundiced, or clubbed. Jugular 
venous pressure was not raised and there was no peripheral edema. Head, ears, nose, 
throat, and neck examinations were normal. Eye exam showed large dilated pupils 
that reacted poorly to light. There was no lymphadenopathy. Pectus excavatum was 
present. Lungs, heart, abdomen, and genitalia were normal. Musculoskeletal exam 
revealed swan neck deformities in the ﬁ  ngers. Extremity examination was normal. He 
had a dry, pruritic and raised erythemic rash on the face and torso.Therapeutics and Clinical Risk Management 2008:4(4) 838
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Cranial nerves II–XII were intact except for dilated pupils 
with minimal reaction to light. Muscle strength and bulk were 
normal. All reﬂ  exes were normal. Sensory exam in the upper 
extremities was unremarkable except for a decrease in prick-
ling pain perception at the right index ﬁ  nger to 10 cm. For the 
lower extremities, prickling pain perception was impaired to 
20 cm on the right and 25 cm on the left as measured from 
the tip of each hallux. Soft touch, vibration perception, joint 
position sense, and 1-g and 10-g monoﬁ  lament pressure test-
ing were intact. Using a neuropathy scoring tool modiﬁ  ed 
from Dyck and Thomas (1987) with a maximum score of 
196, the total neuropathy score was 18 on the right and 16 
on the left, indicating a moderate neuropathy.
On quantitative autonomic function testing (QAFT) using 
heart rate variability measures with an ANX 3.0 machine 
(Ansar Group Inc., Philadelphia, PA) all tests were abnormal 
with Expiration/Inspiration ratio (E/I ratio) = 1.04 (normal 
1.2–1.6), Valsalva ratio = 1.03 (normal 1.2–1.6), and 30:15 
ratio = 1.02 (normal 1.15–1.5).
Quantitative sensory testing (QST) (Vinik et al 1995) 
in the right great toe revealed a deﬁ  cit in vibration percep-
tion to 64 microns (normal 0–31 microns) and a decrease 
in monoﬁ  lament pressure sensation to 4.21 log g (normal 
0–3.95 log g). The warm thermal threshold on the right was 
12.4 °C (normal 0–12.4 °C) and 13.6 °C (normal 0–12.4 °C) 
on the left. Cold pain perception was impaired on the left 
great toe to 29.5 °C (normal 0–23.3 °C) and to 30.6 °C on 
the right. Heat pain perception was bilaterally impaired to 
18 °C (normal 0–17.7 °C).
Laser Doppler blood ﬂ  ow showed decreased perfusion 
levels when compared with the normal range for our young 
population.
Electrolytes, fasting glucose/hemoglobin A1C levels, renal/
liver function testing, lipid/thyroid panels, and prostate speciﬁ  c 
antigen scores were all normal. Erythrocyte sedimentation rates 
were elevated (28 and 48 mm/hr.) as was the C-reactive protein 
at 17.2 mg/L. Antinuclear antibodies (ANA) screening was 
positive at 1:320. Rheumatoid factor and dsDNA antibodies 
were negative. Metabolic proﬁ  le, serum protein electrophore-
sis, and C3/C4 complements were unremarkable. Vitamin D-25 
was low at 17 ng/mL (normal 20–100 ng/mL).
Antibody studies with normal results included: Gastric 
parietal and adrenal cell antibodies, Anti-Hu, MAG IGM, 
GAD-65, C-ANCA, ASIALO-GM1 IGM, GD1a, GD1a 
IGM, GD1b IGM, and ANTI-RI (IFA). Abnormal labora-
tory values were: (1) acetylcholine receptor binding antibody 
of 0.1 nM/L (normal 0.1 nM/L) (2) P-ANCA positive, 
and (3) GD1b IGG antibody positive titer at 1:100 (normal 
1:100). N1E-115 neuroblastoma cells representing sensory 
and autonomic neurons were grown in-vitro in the patient’s 
serum for four days and exhibited normal cell proliferation 
compared to controls (Pittenger et al 1999).
Heavy metal screens for nickel, lead, chromium, copper, 
and mercury proved normal. Rapid Plasma Reagin (RPR), 
Lyme disease titer, Hepatitis C antibody, and HIV assay were 
nonreactive. Cortisol, adrenocorticotropic hormone (ACTH), 
and aldosterone levels were all normal.
Supine norepinephrine was 66 pg/mL (normal 112–658 
pg/mL), epinephrine 20 pg/mL, and dopamine 30 pg/mL. 
Standing norepinephrine was 422 pg/mL (normal 217–1109 
pg/mL). Epinephrine and dopamine did not increase with 
the standing test. Supine blood pressure was 108/66 mmHg 
(pulse – 67 bpm). This dropped to 73/46 mmHg (pulse – 71 
bpm) after one minute of standing. Supine blood pressure was 
89/58 mmHg at 15 minutes with the pulse staying between 
70 to 72 bpm.
Electroencephalography showed abnormal bilateral mid-
temporal independent epileptiform discharges read as “corti-
cal irritability.” Schirmer testing and a gastric emptying study 
were normal. Electrophysiologic testing of peripheral nerve 
function of the peroneal and tibial nerves was normal.
Differential diagnosis
We suspected an autoimmune mechanism for his condition 
since he had Sjogren’s/Sicca syndrome and autonomic nerve 
dysfunction, but we needed to consider other potential causes 
to be certain.
He did not abuse alcohol. His weight loss suggested 
possible malabsorptive issues such as B12 deﬁ  ciency. B12 
deﬁ  ciency was excluded by the absence of macrocytic anemia 
and gastric parietal antibodies.
Familial amyloidosis could produce weight loss, auto-
nomic dysfunction, and orthostatic hypotension. However, he 
had no family history thereof and no organomegaly. A nerve 
biopsy for amyloid using Congo red was negative.
Diabetes could lead to diminished peripheral blood ﬂ  ow, 
decreased intraepidermal nerve ﬁ  bers (see Pathological dis-
cussion), and small ﬁ  ber neuropathy (Pittenger et al 2004; 
Vinik et al 1995). The HgA1C and GAD-65 antibody studies 
were normal (Vinik et al 2005).
Chagas disease was unlikely as he had never traveled to 
Central or South America. A negative Lyme titer ruled out 
Lyme disease. The patient’s RPR screen for syphilis and HIV 
antibody testing were both nonreactive.
Shy-Drager syndrome could present similarly but there 
was no parkinsonism, cerebellar ataxia, cognitive impair-Therapeutics and Clinical Risk Management 2008:4(4) 839
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ment, muscular atrophy, or upper motor neuron involvement 
(Diedrich and Robertson 2005).
While heavy metal exposure has been linked to peripheral 
and autonomic neuropathies, our assays for lead, mercury, nickel, 
chromium, and copper were normal (Rubens et al 2001).
Paraneoplastic syndrome was plausible, but there was no 
cerebellar ataxia, cushingoid characteristics, or visible tumors 
on the CT scan of the chest and abdomen. Cortisol, ACTH, 
and anti-Hu antibody values were likewise normal.
The clinical neuropathic syndromes associated with ace-
tylcholine receptor antibodies and ganglionic receptor-binding 
antibodies could cause this (Vinik et al 2005). Reviewing the 
literature supported the diagnosis of autoimmune-mediated 
autonomic neuropathy. Sandroni and colleagues (2004) 
compared two sets of patients with idiopathic autonomic 
neuropathy: 19 who were seropositive for ganglionic ace-
tylcoline receptor antibodies and 87 who were seronegative. 
There were strong associations in the seropositive group 
with abnormal pupillary reﬂ  exes, sicca complex, lower gas-
trointestinal dysfunction, bladder symptoms, and abnormal 
sweat testing.
Proposed diagnosis
Autoimmune-mediated autonomic neuropathy and arthritis.
Pathological discussion
Figure 1 shows skin biopsies of the forearm and proximal/dis-
tal aspects of the leg to assess nerve content. Samples were 
stained with protein gene product (PGP) 9.5, a ﬂ  uorescent 
marker for intraepidermal nerve ﬁ  bers (IENF). Inspection 
with confocal microscopy revealed a marked decrease in ﬂ  uo-
rescent nerve densities with a lack of nerve projection from the 
dermis into the red-stained epidermis. The patient’s IENF was 
low at all sites – 8.7 vs. 39.9 ± 5.5 (control) in the forearm; 
4.0 vs. 18.6 ± 4.0 (control) in the proximal leg; and 6.2 vs. 
34.7 ± 8.1 (control) in the distal leg. These ﬁ  ndings support 
Pittenger and colleagues (2004) who previously described that 
a decreased IENF correlated to small-ﬁ  ber neuropathy (altered 
warm/cold thermal sense and heat pain threshold).
Management discussion
The patient displayed strong symptomatic, objective, 
biochemical, and autoimmune evidence of dysautonomia. 
Previous therapy with leﬂ  unomide and methotrexate only 
provided relief for the patient’s arthritic component. No 
targeted autonomic neuropathy treatment had been tried.
A search through the literature on the management of 
autoimmune-mediated autonomic neuropathy yielded no 
standardized guidelines.
Area of interest showing depletion of nerve fibers in the
epidermis at all three levels.  
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Figure 1 Pan-reduction of intrapidermal nerve ﬁ  ber (IENF) density in the skin of the forearm, proximal leg, and distal leg with PGP 9.5 (Protein Gene Product) used as a ﬂ  uorescent 
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The patient visited another facility for a second opinion. 
Their results differed from ours in one area: the acetylcholine 
receptor binding antibody level was 0.00 nmol/L (normal 
0.02). No deﬁ  nitive cause for the autonomic dysfunction 
was found and they offered treatment with 9-alpha ﬂ  uoro 
(hydrocortisone).
The possibility of paraneoplastic syndrome remained in 
the differential. Multiple CT scans and a host of biochemical 
markers failed to support this diagnosis, yet the constellation 
of symptoms warranted further consideration of a neoplasm 
even in the absence of positive ﬁ  ndings.
We stopped the leﬂ  unomide and addressed the orthostatic 
hypotension by starting ﬂ  orinef 0.1 mg twice daily and pred-
nisone 1 mg/day to expand the plasma ﬂ  uid volume (Bonnel 
and Graham 2004). Symptomatic relief was obtained by (1) 
lukewarm baths, (2) delayed transitioning to a standing posi-
tion after waking, (3) use of body stockings, (4) liberal salt 
intake, and (5) the use of “NutriNerve” (alpha-lipoic acid, 
gamma linoleic acid, benfotiamine, and borage oil). We 
also started intravenous immunoglobulin (IVIG) therapy at 
1.0 g/kg/day for 2 days on 3 consecutive weeks.
The patient returned a year later with a broken foot from 
a fall. The full cycle of IVIG, ﬂ  orinef, and prednisone pro-
vided no symptomatic relief. The NutriNerve antioxidants 
were discontinued after 45 days. His examination, QAFT, 
QST, and blood ﬂ  ow analysis showed no improvement 
except for QST (see Table 1). This revealed the vibration, 
pressure perception, cold/warm sensation, and heat pain had 
normalized.
At that time, we considered a new therapy option: etaner-
cept. This drug had previously been used to treat peripheral 
neuropathy, but its actions on autonomic neuropathy had 
not been documented (Sommer et al 2001). After carefully 
considering the risks, we started etanercept 50 mg/week. His 
rheumatologist would follow him back home with the next 
visit here in six months.
He returned symptomatically better and recalled having 
just one falling episode from getting up too quickly. He 
gained back some of his weight, began to sweat again, and 
the arthritic pain and swelling had improved. A repeat chest 
CT scan showed a very slight decrease in the size of his 
lymph nodes. GAD-65 autoantibodies, acetylcholine receptor 
antibodies, ANA, serum ACE, vitamin D 1,25 dihydroxy, 
and parathyroid hormone were normal.
Symptoms continued to improve at visits four and ten 
months later. He discontinued the prednisone and reduced 
the ﬂ  orinef to 0.1 mg/day. Swelling in the wrist and hand 
had resolved. Blood pressure readings were 148/99 mmHg 
(pulse – 66 bpm) for supine, 135/91 mmHg (pulse – 65 bpm) 
for sitting, and 90/60 mmHg (pulse – 68 bpm) for stand-
ing. The patient remained asymptomatic throughout these 
measurements.
Current QAFT, QST, and Laser Doppler blood ﬂ  ow 
analysis were compared with the baseline ﬁ  gures from 2004. 
In Figure 2, the post-etanercept basal state function remained 
low. Deep breathing and valsalva responses improved mark-
edly from the baseline study. In Table 1, QST showed notable 
improvements in vibration, pressure, warm/cold thermal per-
ception, and heat pain recognition after IVIG therapy. Etaner-
cept maintained this restoration of nerve function except for 
heat pain recognition. In Figure 3, the Laser Doppler blood 
ﬂ  ow response increased with etanercept, as demonstrated by 
the upward shift of the curve during warming.
Attempts to improve autonomic function have been done 
using zopolrestat, an aldose reductase inhibitor (Johnson et al 
2004). This drug was shown to increase cardiac output and 
left ventricular ejection fraction during exercise in diabetic 
subjects, but had no positive effect in autonomic function 
Table 1 Quantitative sensory tests: baseline, post-IVIG, and post-etanercept treatments. Note the improvement from baseline with 
IVIG and etanercept in vibration and monoﬁ  lament pressure perception as well as warm and cold thermal thresholds
Quantitative sensory tests Baseline
Left great
toe
Baseline
Right great
toe
Post-IVIG
Left great
toe
Post-IVIG
Right great
toe
Post-etanercept 
Left great toe
Post-etanercept 
Right great toe
Vibration (microns) 30.37 64.27 19.70 24.47 28.53 15.23
Pressure (Semmes-Weinstein 
Monoﬁ  laments)
3.41 4.21 2.64 3.12 2.83 2.93
Cold sensation (below 32 ºC) 7.0 10.4 2.9 3.6 3.1 10.9
Warm sensation (above 32 ºC) 13.6 12.4 11.4 6.9 11.7 8.9
Cold pain (below 32 ºC) 29.5 30.6 32.0 26.7 32.0 32.0
Heat pain (above 32 ºC) 18.0 18.0 16.9 14.9 18.0 18.0
Normal Ranges – Vibration (0–31 microns); Pressure (0–3.95 log g); Cold Sensation (0–10.5 ºC); Warm Sensation (0–12.4 ºC); Cold Pain (0–23.3 ºC); and Heat Pain (0–17.7 ºC).Therapeutics and Clinical Risk Management 2008:4(4) 841
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based on heart rate variability (Johnson et al 2004). A 
number of other interventions such as graded exercise, ace 
inhibitors, and spironolactone have been tried with limited 
success (Kontopoulos et al 1997; Gaede et al 1999; Korkmaz 
et al 2000). Our patient’s QAFT demonstrated recovery of 
sympathetic (Valsalva) and parasympathetic (deep breath-
ing) function with etanercept as well as an enhancement of 
peripheral skin blood ﬂ  ow on Laser Doppler studies.
The initial improvement of this patient’s autonomic 
symptoms could have also resulted from the use of alpha-lipoic 
acid and benfotiamine in the antioxidant mixture (Casellini 
and Vinik 2007). In particular, 600 mg/day of alpha-lipoic 
acid has been shown to improve diabetic polyneuropathy 
(including clinical and symptomatic improvement of C-ﬁ  ber 
neuropathy, which is also implicated in autonomic dysfunc-
tion) in a 1,258 patient meta analysis and in the SYDNEY 
2 trial involving 181 subjects (Ziegler et al 2004, 2006). It 
has been suggested that these changes may be related to the 
antioxidant effects on enhanced nerve blood ﬂ  ow (Coppey 
et al 2001; Ziegler et al 2006). Since our patient stopped 
Figure 2 Baseline and post-etanercept quantitative autonomic function tests demonstrating severe reduction in vagal sympathetic tone. Note the improvement in deep 
breathing and Valsalva responses after etanercept treatment.
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Figure 3 Laser Doppler perfusion response to heating for baseline and post-etanercept treatment. The grey area is normal.Therapeutics and Clinical Risk Management 2008:4(4) 842
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NutriNerve after only a month and a half, we conclude his 
continued improvement in autonomic function is from the 
etanercept.
Final diagnosis
Idiopathic autoimmune-mediated autonomic neuropathy and 
arthritis improved with etanercept.
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